J Clin Invest.:Periostin介导慢性过敏性炎症疾病

2012-06-19 bo 生物谷

6月11日,J Clin Invest.杂志在线报道了Periostin(一种细胞基质蛋白)在慢性过敏性炎症疾病中发挥的重要作用。由接触过敏原引发的过敏性炎症常导致慢性炎症性疾病,如遗传性过敏症皮炎(AD)和支气管哮喘的发病。慢性过敏性炎症的机制仍然没有得到解决。 Periostin是最近发现的一种细胞基质蛋白,在人类由POSTN基因编码,作为配体与alpha-V/beta-3和alpha-V/

6月11日,J Clin Invest.杂志在线报道了Periostin(一种细胞基质蛋白)在慢性过敏性炎症疾病中发挥的重要作用。由接触过敏原引发的过敏性炎症常导致慢性炎症性疾病,如遗传性过敏症皮炎(AD)和支气管哮喘的发病。慢性过敏性炎症的机制仍然没有得到解决。

Periostin是最近发现的一种细胞基质蛋白,在人类POSTN基因编码,作为配体与alpha-V/beta-3alpha-V/beta-5整合素相互作用,支持上皮细胞粘附和迁移蛋白质。它与几个细胞表面的整合素分子相互作用,为组织发展和重构提供信息。利用皮肤炎症小鼠模型,研究者发现,periostin是放大和维持过敏性炎症的一个关键的介导因子。 Th2(辅助性T细胞2型)细胞因子IL-4(白介素-4)和IL-13(白介素-13)刺激成纤维细胞产生periostin。Periostin与其在角化细胞上的受体αV整合素相互作用,诱导炎性细胞因子的生产,从而加快了Th2型免疫反应。

因此,抑制periostin或αV整合素阻止过敏引起的皮肤炎症的发生或进展。由此,periostin启动了一个恶性循环,将角化细胞活化与Th2型免疫反应联系在一起,并且在放大和慢性化过敏性皮肤炎过程中发挥关键作用。

该研究,为深入理解慢性过敏性炎症疾病提供了新的启示,并为治疗找到了潜在的靶点。

doi:10.1016/j.cell.2011.10.017
PMC:

PMID:

Periostin promotes chronic allergic inflammation in response to Th2 cytokines

Miho Masuoka1, Hiroshi Shiraishi1, Shoichiro Ohta2, Shoichi Suzuki1, Kazuhiko Arima1, Shigehisa Aoki3, Shuji Toda3, Naoki Inagaki4, Yuichi Kurihara5, Sayaka Hayashida5, Satoshi Takeuchi5, Kenta Koike6, Junya Ono7, Hirokazu Noshiro6, Masutaka Furue5, Simon J. Conway8, Yutaka Narisawa9 and Kenji Izuhara1,2

Allergic inflammation triggered by exposure of an allergen frequently leads to the onset of chronic inflammatory diseases such as atopic dermatitis (AD) and bronchial asthma. The mechanisms underlying chronicity in allergic inflammation remain unresolved. Periostin, a recently characterized matricellular protein, interacts with several cell surface integrin molecules, providing signals for tissue development and remodeling. Here we show that periostin is a critical mediator for the amplification and persistence of allergic inflammation using a mouse model of skin inflammation. Th2 cytokines IL-4 and IL-13 stimulated fibroblasts to produce periostin, which interacted with αv integrin, a functional periostin receptor on keratinocytes, inducing production of proinflammatory cytokines, which consequently accelerated Th2-type immune responses. Accordingly, inhibition of periostin or αv integrin prevented the development or progression of allergen-induced skin inflammation. Thus, periostin sets up a vicious circle that links Th2-type immune responses to keratinocyte activation and plays a critical role in the amplification and chronicity of allergic skin inflammation.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2059199, encodeId=3590205919996, content=<a href='/topic/show?id=5b6d940428a' target=_blank style='color:#2F92EE;'>#过敏性炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94042, encryptionId=5b6d940428a, topicName=过敏性炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Fri Jan 18 18:29:00 CST 2013, time=2013-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046784, encodeId=d1bc2046e84ef, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Sep 30 01:29:00 CST 2012, time=2012-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070766, encodeId=092420e076627, content=<a href='/topic/show?id=83c06e051bf' target=_blank style='color:#2F92EE;'>#炎症疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67051, encryptionId=83c06e051bf, topicName=炎症疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Thu Jan 03 11:29:00 CST 2013, time=2013-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050315, encodeId=4e80205031550, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Mar 19 13:29:00 CST 2013, time=2013-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725433, encodeId=0e261e2543305, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Jul 31 22:29:00 CST 2012, time=2012-07-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2059199, encodeId=3590205919996, content=<a href='/topic/show?id=5b6d940428a' target=_blank style='color:#2F92EE;'>#过敏性炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94042, encryptionId=5b6d940428a, topicName=过敏性炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Fri Jan 18 18:29:00 CST 2013, time=2013-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046784, encodeId=d1bc2046e84ef, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Sep 30 01:29:00 CST 2012, time=2012-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070766, encodeId=092420e076627, content=<a href='/topic/show?id=83c06e051bf' target=_blank style='color:#2F92EE;'>#炎症疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67051, encryptionId=83c06e051bf, topicName=炎症疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Thu Jan 03 11:29:00 CST 2013, time=2013-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050315, encodeId=4e80205031550, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Mar 19 13:29:00 CST 2013, time=2013-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725433, encodeId=0e261e2543305, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Jul 31 22:29:00 CST 2012, time=2012-07-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2059199, encodeId=3590205919996, content=<a href='/topic/show?id=5b6d940428a' target=_blank style='color:#2F92EE;'>#过敏性炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94042, encryptionId=5b6d940428a, topicName=过敏性炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Fri Jan 18 18:29:00 CST 2013, time=2013-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046784, encodeId=d1bc2046e84ef, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Sep 30 01:29:00 CST 2012, time=2012-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070766, encodeId=092420e076627, content=<a href='/topic/show?id=83c06e051bf' target=_blank style='color:#2F92EE;'>#炎症疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67051, encryptionId=83c06e051bf, topicName=炎症疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Thu Jan 03 11:29:00 CST 2013, time=2013-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050315, encodeId=4e80205031550, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Mar 19 13:29:00 CST 2013, time=2013-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725433, encodeId=0e261e2543305, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Jul 31 22:29:00 CST 2012, time=2012-07-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2059199, encodeId=3590205919996, content=<a href='/topic/show?id=5b6d940428a' target=_blank style='color:#2F92EE;'>#过敏性炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94042, encryptionId=5b6d940428a, topicName=过敏性炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Fri Jan 18 18:29:00 CST 2013, time=2013-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046784, encodeId=d1bc2046e84ef, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Sep 30 01:29:00 CST 2012, time=2012-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070766, encodeId=092420e076627, content=<a href='/topic/show?id=83c06e051bf' target=_blank style='color:#2F92EE;'>#炎症疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67051, encryptionId=83c06e051bf, topicName=炎症疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Thu Jan 03 11:29:00 CST 2013, time=2013-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050315, encodeId=4e80205031550, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Mar 19 13:29:00 CST 2013, time=2013-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725433, encodeId=0e261e2543305, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Jul 31 22:29:00 CST 2012, time=2012-07-31, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2059199, encodeId=3590205919996, content=<a href='/topic/show?id=5b6d940428a' target=_blank style='color:#2F92EE;'>#过敏性炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94042, encryptionId=5b6d940428a, topicName=过敏性炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Fri Jan 18 18:29:00 CST 2013, time=2013-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046784, encodeId=d1bc2046e84ef, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Sep 30 01:29:00 CST 2012, time=2012-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070766, encodeId=092420e076627, content=<a href='/topic/show?id=83c06e051bf' target=_blank style='color:#2F92EE;'>#炎症疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67051, encryptionId=83c06e051bf, topicName=炎症疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Thu Jan 03 11:29:00 CST 2013, time=2013-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050315, encodeId=4e80205031550, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Mar 19 13:29:00 CST 2013, time=2013-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725433, encodeId=0e261e2543305, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Jul 31 22:29:00 CST 2012, time=2012-07-31, status=1, ipAttribution=)]
    2012-07-31 feather89

相关资讯

J Altern Complement Med:美药剂师发现中药若与常规药物混服或致命

具有治疗功效的生姜,是一种较为流行的天然补充剂。 美国药剂师凯瑟琳·乌尔布里奇经研究发现,如果将草药和补充疗法与常规药物混合在一起,可能将患者的生命置于危险境地。研究显示天然补充剂与广泛使用的药物混合服用将产生有害的副作用并引发一系列健康问题。 英国约有1000万人常把草药、维生素和矿物质补充剂混服 乌尔布里奇的研究发现,大蒜、生姜、贯叶连翘(圣约翰草)、绿茶等流行的补充剂能够对处方药或者非

J Virol:干细胞疗法为治疗HIV感染另辟蹊径

近日,来自加利福尼亚大学戴维斯分校的研究者使用了一种创新的干细胞疗法来对抗引起AIDS的HIV病毒。研究者刊登在5月份的国际杂志Journal of Virology上的研究文章指出,安全有效的将抗HIV病毒的干细胞移植入小鼠体内可以描述病人感染的模型,这种新型技术是用一种携带有三倍结合的抗HIV的基因的工程干细胞来替代免疫系统,而且被证明是能够发挥正常功能的。 研究者Joseph Anders

Blood Can J:纳米粒子治疗多发性骨髓瘤

近日,圣母大学的研究人员已经研制出一种纳米粒子,该粒子显示出巨大的用于治疗多发性骨髓瘤(MM)的潜力。 治疗MM的临床医生面对的困难之一就是:这种类型的癌细胞对先进的化疗治疗手段产生了耐药性。 化学和生物分子工程助理教Ba?ar Bilgi?er说:我们设计的纳米粒子有多重功效。首先,它们减少了多发性骨髓瘤对阿霉素抗药性的产生。第二,这些纳米粒子实际上可以使得癌细胞尽可能对的接触到药物

J Sex Med.:新研究表明睾酮替代疗法并不增加前列腺癌发病率

根据2012年6月6日在线发表在Journal of Sexual Medicine期刊上的一篇论文,睾酮替代疗法(testosterone replacement therapy, TRT)似乎是安全的,并不增加前列腺癌发病率。 英国伦敦大学学院医院研究员Mark R. Feneley博士和伦敦男性健康中心研究员Malcolm Carruthers博士开展了一项最新的研究:分析接受TRT治疗的

J Dis Mod & Mechan:p53在前列腺癌发展中的重要作用

近日,来自加州大学戴维斯分校的研究者发现了一种遗传突变在前列腺癌的发展过程中扮演着重要角色,以前研究揭示在晚期疾病的发展中会出现p53的突变,但是现在p53绝对不会扮演起始因子的作用了,研究者的这项研究为诊断和治疗疾病开辟了一片新天地。 这项研究成果刊登在了国际著名杂志The Journal Disease Models & Mechanisms上,研究者Alexander表示,我们的研

J Am Coll Cardiol:基因多态性所致血糖升高亦增加心血管风险

  空腹血糖升高是公认的缺血性心脏病(IHD)危险因素,而非空腹血糖与IHD之间的关系尚不明确。日前《美国心脏病学会杂志》(J Am Coll Cardiol)发表的一篇文章表明,与常规非空腹血糖一样,基因多态性导致的血糖升高也与IHD和心肌梗死(MI)风险增加相关。   研究共涉及来自哥本哈根及丹麦80522人的数据,采用孟德尔随机化方法进行分析,其中14155例